12Oct 2023
Revised IWG 2023 Criteria for Complete Response to Azacitidine Improved Prognostic Value in Higher-Risk Myelodysplastic Syndromes Patients

Revised IWG 2023 Criteria for Complete Response to Azacitidine Improved Prognostic Value in Higher-Risk Myelodysplastic Syndromes Patients

A recent study examined the impact of revised response criteria (IWG2023) on prognosis in higher-risk myelodysplastic syndromes (HR-MDS) patients treated with azacitidine. The study found that the new criteria, particularly the lowered hemoglobin cutoff value, provided better prognosis prediction compared to the older IWG2006 criteria. However, additional research with larger patient populations is needed to validate these findings and assess the significance of other criteria changes. This study underscores the importance of accurate response classification for treatment outcomes in HR-MDS patients.

  • #oncology

Like

Save

Share